EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Emergent BioSolutions's enterprise value is $851 Mil.
Emergent BioSolutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-519 Mil. Therefore, Emergent BioSolutions's EV-to-EBITDA for today is -1.64.
The historical rank and industry rank for Emergent BioSolutions's EV-to-EBITDA or its related term are showing as below:
EBS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.5 Med: 10.36 Max: 38.39
Current: -1.64
During the past 13 years, the highest EV-to-EBITDA of Emergent BioSolutions was 38.39. The lowest was -45.50. And the median was 10.36.
EBS's EV-to-EBITDA is ranked worse than 100% of 707
companies
in the Drug Manufacturers industry
Industry Median: 14.03
vs EBS: -1.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Emergent BioSolutions EV-to-EBITDA Historical Data
The historical data trend for Emergent BioSolutions's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Emergent BioSolutions's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's EV-to-EBITDA falls into.
Emergent BioSolutions's current Enterprise Value is $851 Mil.
Emergent BioSolutions's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-519 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Emergent BioSolutions's PE Ratio for today is calculated as:
Emergent BioSolutions's share price for today is $1.935.
Emergent BioSolutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Emergent BioSolutions (Emergent BioSolutions) Business Description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EBS has been successfully added to your 